title: Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy).
abstract: BACKGROUND
  Data on clinical outcomes among patients treated with the zotarolimus-eluting Endeavor™ stent versus the sirolimus-eluting Cypher™ stent favor the sirolimus-eluting stent. However, a separate comparison of clinical outcome among patients treated for multiple lesions with these stents is lacking. We performed this comparison within the SORT OUT III trial data set.
  
  
  METHODS
  Among 2332 patients randomized in SORT OUT III, 695 were treated for multiple lesions with zotarolimus-eluting (n = 350) or sirolimus-eluting (n = 345) stents and followed for 18 months. Major adverse cardiac events (MACE); composite of cardiac death, myocardial infarction, or target vessel revascularization (TVR); was the primary endpoint.
  
  
  RESULTS
  Zotarolimus-eluting compared to sirolimus-eluting stent treatment was associated with increased MACE rate (13.2% vs. 2.6%; hazard ratio 5.29 with 95% confidence interval: 2.59-10.8). All secondary endpoints; all cause death, cardiac death, myocardial infarction, TVR, target lesion revascularization, in-stent restenosis, and definite stent thrombosis; were observed more frequently among zotarolimus-eluting stent treated patients. For all endpoints, hazard ratios were 1.6 to 4.6 times higher than in the overall results of the SORT OUT III trial.
  
  
  CONCLUSIONS
  We observed better clinical outcomes among patients treated for multiple lesions with the sirolimus-eluting stent compared to those treated with the zotarolimus-eluting stent.
authors.affiliation: Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. troels.thim@ki.au.dk
authors.forename: Troels
authors.initials: T
authors.lastname: Thim
authors.forename: Michael
authors.initials: M
authors.lastname: Maeng
authors.forename: Jens Flensted
authors.initials: JF
authors.lastname: Lassen
authors.forename: Anne
authors.initials: A
authors.lastname: Kaltoft
authors.forename: Lisette Okkels
authors.initials: LO
authors.lastname: Jensen
authors.forename: Jan
authors.initials: J
authors.lastname: Ravkilde
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.forename: Søren
authors.initials: S
authors.lastname: Galatius
authors.forename: Evald Høj
authors.initials: EH
authors.lastname: Christiansen
authors.forename: Thomas
authors.initials: T
authors.lastname: Engstrøm
authors.forename: Morten
authors.initials: M
authors.lastname: Madsen
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: Hans Henrik
authors.initials: HH
authors.lastname: Tilsted
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000209:etiology / Q000628:therapy; D020123:Sirolimus / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013927:Thrombosis / Q000628:therapy; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus